Technology
Health
Pharmaceutical
Arcus Biosciences
$8.969876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$8.96
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$0.08 (-0.88%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell RCUS and other stocks, options, ETFs, and crypto commission-free!
About
Arcus Biosciences, Inc. engages in the development and commercialization of immunotherapies. The firm compete in the segments of the pharmaceutical, biotechnology and other related markets that develop immunotherapies for the treatment of cancer. Read More The company was founded by Terry J. Rosen and Juan Carlos Jaen in 2015 and is headquartered in Hayward, CA.
Employees
108
Headquarters
Hayward, California
Founded
2015
Market Cap
399.03M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
142.18K
High Today
$9.40
Low Today
$8.91
Open Price
$9.34
Volume
42.93K
52 Week High
$17.50
52 Week Low
$8.57
Collections
Technology
Health
Pharmaceutical
Biotechnology
Cancer Prevention
2018 IPO
US
North America
News
Yahoo FinanceMay 9
Is Arcus Biosciences, Inc. A Good Stock To Buy?
Is Arcus Biosciences, Inc. (NYSE:RCUS) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage of news stories covering failed hedge fund investments and it is a fact that hedge funds' picks don't beat the market 100% of the time, but their consensus picks have histor...
Yahoo FinanceMay 2
Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122
HAYWARD, Calif. and ANN ARBOR, Mich.--(BUSINESS WIRE)-- - Leverages Strata Oncology’s Proprietary Biomarker Technology to Stratify Patients - Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, today announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarker...
Simply Wall StApr 28
What Kind Of Shareholder Appears On The Arcus Biosciences, Inc.’s (NYSE:RCUS) Shareholder Register?
A look at the shareholders of Arcus Biosciences, Inc. (NYSE:RCUS) can tell us which group is most powerful. Generally speaking, as a company grows, institutions will increase their ownership. Conversely, insiders often decrease their ownership over time. I generally like to see some degree of insider ownership, even if only a little. As Nassim Nicholas Taleb said, ‘Don’t tell me what you think, tell me what you have in your portfolio.’ With a market capitalization of US$484m, Arcus Biosciences is a small c...
Price Paid on Robinhood
26% Lower
Right Now
52 Week Low
$8.57
Average Price Paid
$12.04
52 Week High
$17.50
Earnings
-$1.37
-$1.00
-$0.62
-$0.25
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Q1 2019
Q2 2019
Estimated
—
Actual
Expected Aug 6, Pre-Market